ArticleFrontiers in pharmacology2017
Multi-Target Screening and Experimental Validation of Natural Products from
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Exploring graph-based models for predicting active compounds against triple-negative breast cancer.Molecular diversity · 2026Article
- A near-infrared fluorescent probe for dynamic HClO monitoring in epilepsy and high-throughput discovery of natural neuroprotectants.Redox biology · 2025Article
- Molecular docking analysis of flavonoids with AChE and BACE-1.Bioinformation · 2024Article
- Automated machine learning approach for developing a quantitative structure-activity relationship model for cardiac steroid inhibition of NaPharmacological reports : PR · 2023Article
- In Silico Identification of Anti-SARS-CoV-2 Medicinal Plants Using Cheminformatics and Machine Learning.Molecules (Basel, Switzerland) · 2022Article
- Article
- Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer's treatment.Annals of medicine · 2021Article
- Article
- Recent advances in screening active components from natural products based on bioaffinity techniques.Acta pharmaceutica Sinica. B · 2020Review
- Network Pharmacology-Based and Experimental Identification of the Effects of Quercetin on Alzheimer's Disease.Frontiers in aging neuroscience · 2020Article
- Trilobatin Protects Against AβFrontiers in pharmacology · 2020Article
- Neuroprotective Effects of Quercetin in Alzheimer's Disease.Biomolecules · 2019Review
- Embelin, a Potent Molecule for Alzheimer's Disease: A Proof of Concept From Blood-Brain Barrier Permeability, Acetylcholinesterase Inhibition and Molecular Docking Studies.Frontiers in neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder which is considered to be the most common cause of dementia. It has a greater impact not only on the learning and memory disturbances but also on social and economy. Currently, there are mainly single-target drugs for AD treatment but the complexity and multiple etiologies of AD make them difficult to obtain desirable therapeutic effects. Therefore, the choice of multi-target drugs will be a potential effective strategy inAD treatment. To find multi-target active ingredients for AD treatment from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.